Untitled

doi:10.26655/jmchemsci.2023.2.23

Cited by 2 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subfatin is believed to be effective in glucose metabolism because it enhances insulin sensitivity in the adipose tissue by upregulating (PPAR-γ) expression [53]. According to certain theories, overexpression of subfatin may result in decreased lipogenesis and insulin resistance by inhibiting the expression of PPAR-γ in adipocytes [28,54] .…”

Section: Type 2 Diabetes Mellitus and Subfatinmentioning

confidence: 99%

A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus

Ahmed abed,

Othman Farhan,

Noori Salman

et al. 2023

UTJsci

View full text Add to dashboard Cite

Adipokines are essential for maintaining cardiovascular and metabolic balance. The term "adipokines" refers to peptides in the pancreas, brain, vascular system, liver, immune system and muscle. adipokines regulate numbers of factors, such as energy expenditure, hunger, satiety, insulin sensitivity, and blood pressure, insulin secretion, adipogenesis and fat distribution, and that might make them play a role in future pharmacological treatment strategies for obesity and metabolic diseases. Isthmin-1 (Ism-1) is a recently discovered insulin-like adipokine that suppresses hepatic lipids. According to recent research, Ism-1 can enhance lipid metabolism and treat metabolic disorders linked to type 2 diabetic mellitus (T2DM). The primary source of the protein subfatin (SUB) is white adipose tissue. Subfatin (SUB) is expressed in these following tissues: adipose tissue, brain tissue, thymus gland, liver, activated human monocytes, spleen, omental adipose tissue, muscle, salivary glands and heart tissues. The SUB lowers insulin resistance to control glucose metabolism. Isthmian-1 is a novel biomarker for early management and diagnosis of T2DM and has a beneficial effect in glucose homeostasis and might be therapeutic for diabetes. Subfatin also plays a role in glucose metabolism and insulin sensitivity, so it has significant effect in pathogenesis and complication of diabetes.

show abstract

Section: Type 2 Diabetes Mellitus and Subfatinmentioning

confidence: 99%

A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus

Ahmed abed,

Othman Farhan,

Noori Salman

et al. 2023

UTJsci

View full text Add to dashboard Cite

show abstract

“…Inhibiting the (nuclear factor erythroid2-related factor 2) (Nrf2) pathway caused asprosin overexpression in adipocytes and speed up the lipid deposition process [42].…”

Section: Asprosin and Adipocyte:-mentioning

confidence: 99%

Review of Asprosin as new Biomarker for diagnosis different Diseases

Ehssan,

Baydaa Ahmed Abed,

Isam Noori Salman

et al. 2023

UTJsci

View full text Add to dashboard Cite

This study was designed to investigate the connections between (Inflammation, Cardiovascular diseases (CVDs),-diabetes mellitus,-Obesity,-polycystic ovary syndrome, thyroid and cancer )-and asprosin hormone. Asprosin is present in high amounts in a variety of diseases that are considerably manifested in several cases and illnesses Asprosin hormone is newly adipokine helps the liver produce glucose. White adipose tissue secretes the novel hormone asprosin, which stimulates the release of hepatic glucose, making protein a possible target for new treatments for obesity and type 2 diabetes mellitus. Exons (65 and 66) of the gene( Fibrillin 1 (FBN1)), which was recently shown to be a new hormone released by white adipose tissues, are the final two exons that code for asprosin. However, further research is needed to fully understand how asprosin affects pancreatic beta-cells, leading to pathologically elevated cellular dysfunction and inflammation. Asprosin hormone is raised in human with metabolic disease. The findings imply that asprosin hormone may be crucial for maintaining insulin and glucose homeostasis as well as acting as a risk factor for a number of diseases, including CVDs, obesity, T2DM, cancer, hypothyroidism, and PCOS. Depleting asprosin or attenuating its activity may potentially offer a novel therapeutic option for the treatment of T2DM and obesity.

show abstract

Untitled

Cited by 2 publications

References 19 publications

A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus

A review on the role of novel adipokine Isthmin-1 and Subfatin in human type 2 diabetes mellitus

Review of Asprosin as new Biomarker for diagnosis different Diseases

Contact Info

Product

Resources

About